This was a prospective cohort study using data from pregnant participants in the US Environmental Influences on Child Health Outcomes (ECHO) program. Researchers analyzed 2,696 third-trimester study visits from 1,898 pregnant individuals. Urine samples were tested for 20 phthalate metabolites, and blood pressure was measured later in pregnancy. The main outcomes were systolic and diastolic blood pressure and risk of gestational hypertension/preeclampsia.
Higher urinary levels of several phthalate metabolites were associated with higher diastolic blood pressure, especially in the late third trimester. Metabolites of DEHP showed some of the more consistent associations with elevated blood pressure measures. Associations with actual diagnoses of gestational hypertension or preeclampsia were weaker and less consistent, and in some analyses not statistically significant. The results point to modest blood pressure changes at a population level, not large jumps in individual patients.
The study used spot urine samples, which capture short-term phthalate exposure and may not fully represent overall exposure across pregnancy. Observational design means associations cannot prove that phthalates cause higher blood pressure; unmeasured factors (diet quality, other chemicals, socioeconomic stress) may influence results. The increased blood pressure observed was modest and does not translate directly into a clear individual risk for hypertensive disorders. The population was from US cohorts and may not generalize to all communities or countries, and the paper notes the possibility of exposure misclassification and residual confounding.
This study strengthens the growing body of evidence linking endocrine-disrupting chemicals to cardiometabolic changes in pregnancy. The large sample, repeated measurements, and adjustment for many confounders are strengths, but single-spot urine sampling and residual confounding (diet, stress, unmeasured exposures) limit causal interpretation. Effect sizes were modest, suggesting phthalates are one of many contributors to gestational blood pressure changes rather than the main driver. Findings are broadly consistent with prior work on environmental chemicals and hypertensive disorders of pregnancy, but the clinical impact for an individual patient remains uncertain and likely depends on combined metabolic, vascular, and inflammatory vulnerabilities.
Encourage pregnant patients to limit unnecessary plastic and synthetic fragrance exposure (e.g., avoid heating food in plastic, reduce use of scented products, choose phthalate-free personal care items) as part of a broader lifestyle plan, recognizing evidence is suggestive, not definitive. Emphasize regular blood pressure monitoring in pregnancy, especially for those with other risk factors (history of hypertension, obesity, insulin resistance, autoimmune disease). Integrate environmental exposure questions into root-cause assessments of gestational hypertension alongside nutrition, sleep, stress, inflammation, and metabolic health. Frame phthalate reduction as a low-risk supportive measure, not a guarantee to prevent high blood pressure or pregnancy complications.
This study followed pregnant people and checked their urine for phthalates, chemicals commonly found in plastics and many personal care products. Those with higher levels of certain phthalate byproducts tended to have slightly higher blood pressure later in pregnancy. This does not prove that phthalates cause high blood pressure, but it suggests they may be one more stressor on the body during an already demanding time. For someone focusing on root causes of reproductive and pregnancy health, it supports paying attention not only to hormones, blood sugar, and inflammation, but also to everyday chemical exposures—while still working closely with your clinician for regular blood pressure checks and personalized care.
Consider adding targeted environmental history (plastic food storage/heating, canned foods, fragranced products, occupational exposures) to assessments of patients at risk for gestational hypertension or preeclampsia. While effect sizes were modest, they align with an emerging pattern of endocrine-disrupting chemicals contributing to endothelial dysfunction, oxidative stress, and subtle blood pressure elevations, particularly via DEHP metabolites. Integrate this with existing restorative protocols: optimize preconception weight, insulin sensitivity, micronutrient status (e.g., magnesium, calcium, vitamin D), sleep, and vascular health while suggesting practical exposure reductions (glass/stainless containers, avoiding microwaving in plastic, low-fragrance products). Monitor blood pressure, urine protein, and metabolic markers (fasting glucose/insulin, lipids) as usual and treat any red flags (headache, vision changes, rapid swelling, right upper quadrant pain) as urgent, referring promptly according to obstetric guidelines; environmental counseling is adjunctive, not a replacement for standard hypertensive disorder management.
Educational insights, not a diagnosis or individualized treatment advice. Discuss findings with your own clinician. Visit Reproductive Health Insights to explore fertility resources.